From March 1983 to December 1989 we observed 36 patients with metastatic transitional cell carcinoma of the urinary tract. We treated 22 patients with M-VAC regimen and 14 patients with MP regimen. Overall response rate (CR + PR) was 71.4% in M-VAC group and 50% in MP group. The patients that had PR were 15 and 8 of them underwent surgery of residual disease. One patient had pathological CR and 6 were free of disease after surgical treatment. Out of 7 patients without cancer after surgery, 3 are alive and free of disease after 84, 42 and 26 months. We didn't have surgical complications. Surgery of residual disease after chemotherapy, when possible, is reliable.
CarmichaelJ., CornbleetM.A., LaurieS., DuncamW., WolfR., SmythJ.: Clinical and laboratory evaluation of methotrexate and cisplatinum for the treatment of advanced bladder cancer (abstract). Proc. ECCO, 2: 150, 1983.
2.
SternbergC.N., YagodaA., ScherH.I., HollanderP., WatsonR.C., AhmedT.: Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) for transitional cell carcinoma of the urothelium (abstract). Proc. Am. Soc. Clin. Oncol., 3: 156, 1984.
3.
PizzocaroG., MilaniA., PivaL., FaustiniM.: Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. Europ. Urol., 20: 89–92, 1991.
4.
SternbergC.N., YagodaA., ScherH.I., WatsonR.C., GellerN., HerrU.W., MorseM.J., SoganiP.C., VaughanE.D., BanderN., WeiselbergL., RosadoK., SmartT., Yun LinS., PenembergD., FairW.R., WhitmoreW.F.: Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium. Cancer, 64: 2448–2458, 1989.
5.
CarmichaelJ., CornbleetM.A., MacDougallR.H., AllanS.G., DuncannW., ChisolmG.D., SmythJ.F.: Cisplatin and methotrexate in the treatment of transitional cell carcinoma of the urinary tract. Br. J. Urol., 57: 299–302, 1985.
6.
StoterG., SplinterT.A.W., ChildJ.A., FossaS.D., DenisL., Van OosteronA.T., De PawM., SilvesterR.: EORTC GU group: Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J. Urol., 137: 662–667, 1987.
7.
SternbergC.N., YagodaA., ScherH.I., WatsonR.C., AhmedT., WeiselbergL.R., GellerN., HollanderP.S., HerrH.W., SoganiP.C., MorseM.J., WhitmoreW.F.: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol., 133: 403–407, 1985.
8.
SternbergC.N., YagodaA., ScherH.I., WatsonR.C., HerrH.W., MorseM.J., SoganiP.C., VaughanE.D., BanderN., WeiselbergL.R., GellerN., HollanderP.S., LippermanR., FairW.R., WhitmoreW.F.: M-VAC (methotrezate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J. Urol., 139: 461–469, 1988.
9.
MilaniA., PivaL., ZanoniF., SalvioniR., AguzziE., PizzocaroG.: Trattamento chemio-chirurgico degli urotelogia metastatizzati. Proc. XXIX Corso Superiore di Oncologia Clinica. Milano, 1988, 12.
10.
LongothetisC., DexeusF., SellaA., AmatoR., FinnL.: A prospective randomized trial of Cisca versus M-VAC chemotherapy in advanced metastatic urothelial tumors (abstract). J. Urol., 141A: 216, 1989.
